On January 6, 2026, in Lille, Cambridge, and Zurich, GENFIT (Euronext: GNFT), a biopharmaceutical company, revealed promising results for their lead investigational drug candidate, G1090N, targeted at treating Acute-On-Chronic Liver Failure (ACLF). The drug, a small molecule, displayed positive Phase 1 safety outcomes and exhibited potent anti-inflammatory properties in ex-vivo research. GENFIT focuses on assisting patients with rare and severe liver disorders.